相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
John M. S. Bartlett et al.
EUROPEAN JOURNAL OF CANCER (2017)
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
Sukhbinder Dhesy-Thind et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Peyman Hadji et al.
JOURNAL OF BONE ONCOLOGY (2017)
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
Jessalyn M. Ubellacker et al.
BREAST CANCER RESEARCH (2017)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant et al.
LANCET (2015)
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
M. Dowsett et al.
LANCET (2015)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
R. Coleman et al.
LANCET (2015)
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
M. Gnant et al.
ANNALS OF ONCOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting
Carmel Jacobs et al.
JOURNAL OF BONE ONCOLOGY (2015)
Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo
Penelope D. Ottewell et al.
CLINICAL CANCER RESEARCH (2014)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
Robert Coleman et al.
LANCET ONCOLOGY (2014)
Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer Results From the Randomized Clinical Trials of Alendronate and Zoledronic Acid
Trisha F. Hue et al.
JAMA INTERNAL MEDICINE (2014)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
R. Coleman et al.
ANNALS OF ONCOLOGY (2013)
Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations
Peyman Hadji et al.
CANCER TREATMENT REVIEWS (2012)
Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature
Michael Gnant et al.
CANCER TREATMENT REVIEWS (2012)
Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo
H. K. Brown et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group
Peter C. Dubsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Systematic Review of Bone Health in Older Women Treated with Aromatase Inhibitors for Early-Stage Breast Cancer
Taryn Becker et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2012)
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
Alexander H. G. Paterson et al.
LANCET ONCOLOGY (2012)
Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class
Philippe Clezardin
BONE (2011)
Dosing of zoledronic acid throughout the treatment continuum in breast cancer
Peyman Hadji et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Use of Bisphosphonates and Reduced Risk of Colorectal Cancer
Gad Rennert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
Michael Gnant et al.
LANCET ONCOLOGY (2011)
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Robert E. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer
Chris R. Cardwell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism
Michael J. Rogers et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial
Rebecca Aft et al.
LANCET ONCOLOGY (2010)
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort
Jane Green et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Anti-tumour activity of bisphosphonates in preclinical models of breast cancer
Ingunn Holen et al.
BREAST CANCER RESEARCH (2010)
Prevention of bone metastases and management of bone health in early breast cancer
Michael Gnant et al.
BREAST CANCER RESEARCH (2010)
In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients
Daniele Santini et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Tumor Self-Seeding by Circulating Cancer Cells
Mi-Young Kim et al.
CELL (2009)
Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA study
Vincent Launay-Vacher et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow-a long-term follow-up
I. J. Diel et al.
ANNALS OF ONCOLOGY (2008)
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
Richard Eastell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Michael Gnant et al.
LANCET ONCOLOGY (2008)
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
Raimund Jakesz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Meta-analysis of clodronate and breast cancer survival
T. C. Ha et al.
BRITISH JOURNAL OF CANCER (2007)
The safety of zoledronic acid
Allan Lipton
EXPERT OPINION ON DRUG SAFETY (2007)
Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells:: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens
Craig T. Morita et al.
IMMUNOLOGICAL REVIEWS (2007)
Preparing the Soil: The premetastatic niche
Rosandra N. Kaplan et al.
CANCER RESEARCH (2006)
The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France
Joyce A. Cramer et al.
CLINICAL THERAPEUTICS (2006)
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
T Powles et al.
BREAST CANCER RESEARCH (2006)
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis
JA Cramer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens
P Conte et al.
ONCOLOGIST (2004)
Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption
A Ezra et al.
ADVANCED DRUG DELIVERY REVIEWS (2000)
分享论文
